CAS: 30766-11-1; 5-Bromopicolinic Acid

相似化合物

29682-15-3 31181-90-5 88139-91-7

上下游产品

CAS号624-28-2 2,5-二溴吡啶 | CAS号124-38-9 二氧化碳 | CAS号97483-77-7 5-溴-2-氰基吡啶 | CAS号31181-90-5 5-溴吡啶-2-甲醛 | CAS号845306-08-3 5-溴吡啶甲酸叔丁酯 | CAS号3430-13-5 5-溴-2-甲基吡啶 | CAS号4214-76-0 2-氨基-5-硝基吡啶 | CAS号4487-59-6 2-溴-5-硝基吡啶 | CAS号21684-59-3 6-甲基吡啶-3-甲酸乙酯 | CAS号436799-32-5 5-溴-2-(三氟甲基)吡啶 | CAS号90145-48-5 5-溴吡啶甲酰胺 | CAS号957063-06-8 (5-溴吡啶-2-基)(吗啉)甲酮 | CAS号845306-08-3 5-溴吡啶甲酸叔丁酯 | CAS号845305-88-6 5-溴-N-乙基吡啶-2-甲酰胺 | CAS号845305-87-5 N-甲基-5-溴吡啶甲酰胺 | CAS号845826-99-5 5-(4-氟苯基)吡啶-2-甲酸 | CAS号97483-77-7 5-溴-2-氰基吡啶 | CAS号88139-91-7 5-溴-2-吡啶甲醇 | CAS号77199-09-8 5-溴-2-吡啶甲酸乙酯

6-甲基-3-吡啶羰基叠氮化物置于氢氧化钾,Potassium Permanganate,Potassium Nitrite,硫酸体系中,化学反应生成 5-溴-2-吡啶羧酸
参考文献:Graf,Journal Fur Praktische Chemie (Leipzig 1954),1932,Vol. <2> 133,P. 36,49
标题:Graf,Journal Fur Praktische Chemie (Leipzig 1954),1932,Vol. <2> 133,P. 36,49

专利信息

专利号:US-2004101523-A1
优先权日:1989-07-27
标题:Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase inhibitors, of which N-acetyl-γ-glutamyl fusaric acid hydrazide (shown below) is preferred.

专利号:WO-9101724-A1
优先权日:1989-07-27
标题 :Renal-selective prodrugs for the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as depa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitors compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase inhibitors, of which N-acetyl-Y-glutamyl fusaric acid is preferred.

专利号:WO-9201667-A1
优先权日:1990-07-25
标题 :Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kydney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase-inhibitors, of which N-acetyl-η-glutamyl fusaric acid hydrazide [represented in formula (a)] is preferred.

专利号:US-RE41998-E
优先权日:1990-02-26
标题 :Compositions and methods of treatment of sympathetically maintained pain
发明人：CAMPBELL JAMES N
权利人:ARCLON THERAPEUTICS INC
摘要:Sympathetically maintained pain is treated topically by administering to the site where sympathetically maintained pain is present an α-1-adrenergic antagonist, α-2-adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic norepinephrine, known collectively as sympatholytic agents. Chemical formulas for several sympatholytic agents are given.

专利号:US-10995078-B2
优先权日:2013-03-13
标 题:Compounds and compositions for inhibition of FASN
发明人：BAIR KENNETH W; LANCIA JR DAVID R; LI HONGBIN; LOCH JAMES; LU WEI; MARTIN MATTHEW W; MILLAN DAVID S; SCHILLER SHAWN E R; TEBBE MARK J
权利人:FORMA THERAPEUTICS INC
摘要:The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

专利号:US-2012202787-A1
优先权日:2009-10-20
标 题:Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators
发明人：AM ENDE CHRISTOPHER WILLIAM; JOHNSON DOUGLAS SCOTT; PETTERSSON MARTIN YOUNGJIN; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN
权利人:AM ENDE CHRISTOPHER WILLIAM; JOHNSON DOUGLAS SCOTT; PETTERSSON MARTIN YOUNGJIN; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I; n n n n n n n n n n as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.